TY - JOUR
T1 - Economic Burden of Fatigue in Inflammatory Bowel Disease
AU - Ananthakrishnan, Ashwin N.
AU - Desai, Raj
AU - Lee, Wan Ju
AU - Griffith, Jenny
AU - Chen, Naijun
AU - Loftus, Edward V.
N1 - Publisher Copyright:
© 2023 The Author(s). Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.
PY - 2023/7/1
Y1 - 2023/7/1
N2 - Background: This retrospective study gathered medical/pharmacy claims data on patients with inflammatory bowel disease (IBD) between January 01, 2000 and March 31, 2019 from the IBM MarketScan commercial claims database to assess the real-world impact of fatigue on healthcare costs in patients newly diagnosed with IBD. Methods: Eligible participants were ≥18 years, newly diagnosed with IBD (≥2 separate claims), and had ≥12 months of continuous database enrollment before and after fatigue diagnosis. The date of fatigue diagnosis was the index date; participants were followed for 12 months post-index. Patients with (cases) or without (controls) fatigue were matched 1:1 by propensity score matching. Patients with evidence of prior IBD diagnosis/treatment, or those with a chronic disease other than IBD wherein fatigue is the primary symptom, were excluded. Healthcare resource utilization (HCRU), including hospitalizations, inpatient and outpatient visits, and associated costs were compared between cases and controls. Results: Matched IBD cohorts (21 321 cases/21 321 controls) were identified (42% Crohn's disease [CD] and 58% ulcerative colitis [UC]) with similar baseline characteristics (average age: 46 years; 60% female). Cases versus controls had significantly more all-cause outpatient visits (incidence rate ratio [IRR], 95% confidence intervals [95% CI]: 1.64 [1.61, 1.67], P <. 001) and all-cause hospitalizations (IRR [95% CI]: 1.92 [1.81, 2.04], P <. 001); as well as significantly higher all-cause total direct healthcare costs (mean: $24 620 vs. $15 324; P <. 001). Similar findings were observed for IBD-related outcomes, as well as in CD- and UC-specific subgroups. Conclusions: Presence of fatigue is associated with an increase in HCRU and total medical costs among patients newly diagnosed with IBD.
AB - Background: This retrospective study gathered medical/pharmacy claims data on patients with inflammatory bowel disease (IBD) between January 01, 2000 and March 31, 2019 from the IBM MarketScan commercial claims database to assess the real-world impact of fatigue on healthcare costs in patients newly diagnosed with IBD. Methods: Eligible participants were ≥18 years, newly diagnosed with IBD (≥2 separate claims), and had ≥12 months of continuous database enrollment before and after fatigue diagnosis. The date of fatigue diagnosis was the index date; participants were followed for 12 months post-index. Patients with (cases) or without (controls) fatigue were matched 1:1 by propensity score matching. Patients with evidence of prior IBD diagnosis/treatment, or those with a chronic disease other than IBD wherein fatigue is the primary symptom, were excluded. Healthcare resource utilization (HCRU), including hospitalizations, inpatient and outpatient visits, and associated costs were compared between cases and controls. Results: Matched IBD cohorts (21 321 cases/21 321 controls) were identified (42% Crohn's disease [CD] and 58% ulcerative colitis [UC]) with similar baseline characteristics (average age: 46 years; 60% female). Cases versus controls had significantly more all-cause outpatient visits (incidence rate ratio [IRR], 95% confidence intervals [95% CI]: 1.64 [1.61, 1.67], P <. 001) and all-cause hospitalizations (IRR [95% CI]: 1.92 [1.81, 2.04], P <. 001); as well as significantly higher all-cause total direct healthcare costs (mean: $24 620 vs. $15 324; P <. 001). Similar findings were observed for IBD-related outcomes, as well as in CD- and UC-specific subgroups. Conclusions: Presence of fatigue is associated with an increase in HCRU and total medical costs among patients newly diagnosed with IBD.
KW - Crohn's disease
KW - economic impact
KW - fatigue
KW - inflammatory bowel disease
KW - ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=85172347894&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85172347894&partnerID=8YFLogxK
U2 - 10.1093/crocol/otad020
DO - 10.1093/crocol/otad020
M3 - Article
AN - SCOPUS:85172347894
SN - 2631-827X
VL - 5
JO - Crohn's and Colitis 360
JF - Crohn's and Colitis 360
IS - 3
M1 - otad020
ER -